122 related articles for article (PubMed ID: 28751150)
1. Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana.
Rajput R; Dangi A; Singh H
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S1013-S1016. PubMed ID: 28751150
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis: an OGTT Study.
Ursini F; Russo E; D'Angelo S; Arturi F; Hribal ML; D'Antona L; Bruno C; Tripepi G; Naty S; De Sarro G; Olivieri I; Grembiale RD
Medicine (Baltimore); 2016 Feb; 95(7):e2552. PubMed ID: 26886599
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
5. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
[TBL] [Abstract][Full Text] [Related]
6. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
7. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
8. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
10. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
11. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in Iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity.
Shakiba Y; Koopah S; Jamshidi AR; Amirzargar AA; Massoud A; Kiani A; Nicknam MH; Nazari B; Nikbin B
Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):147-56. PubMed ID: 24659118
[TBL] [Abstract][Full Text] [Related]
12. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
Lutf A; Poil AR; Hammoudeh M
Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis.
Shen R; Ren X; Jing R; Shen X; Chen J; Ju S; Yang C
Lab Med; 2015; 46(3):226-9. PubMed ID: 26199263
[TBL] [Abstract][Full Text] [Related]
16. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
[TBL] [Abstract][Full Text] [Related]
17. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.
Wang GY; Zhang SL; Wang XR; Feng M; Li C; An Y; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Yan HM; Wang GC; Lu X; Liu X; Zhu P; Chen LN; Jin HT; Liu JT; Guo HF; Chen HY; Xie JL; Wei P; Wang JX; Liu XY; Sun L; Cui LF; Shu R; Liu BL; Yu P; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Han SL; Yang XY; Li H; Huang CB; Gao M; Lai B; Cheng YJ; Li XF; Song LJ; Yu XX; Wang AX; Wu LJ; Wang YH; He L; Sun WW; Gong L; Wang XY; Wang Y; Zhao Y; Li XX; Wang Y; Zhang Y; Su Y; Zhang CF; Mu R; Li ZG
Clin Rheumatol; 2015 Feb; 34(2):221-30. PubMed ID: 25413735
[TBL] [Abstract][Full Text] [Related]
18. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA
Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
[TBL] [Abstract][Full Text] [Related]
19. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
